505 results on '"Gueyffier F"'
Search Results
152. Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial
- Author
-
Boissonnat Pascale, Gaillard Ségolène, Mercier Catherine, Redonnet Michel, Lelong Bernard, Mattei Marie-Françoise, Mouly-Bandini Annick, Pattier Sabine, Sirinelli Agnès, Epailly Eric, Varnous Shaida, Billes Marc-Alain, Sebbag Laurent, Ecochard René, Cornu Catherine, and Gueyffier François
- Subjects
Calcineurin inhibition ,Cyclosporine A ,Heart transplantation ,Renal function ,Randomised clinical trial ,Medicine (General) ,R5-920 - Abstract
Abstract Background Using reduced doses of Cyclosporine A immediately after heart transplantation in clinical trials may suggest benefits for renal function by reducing serum creatinine levels without a significant change in clinical endpoints. However, these trials were not sufficiently powered to prove clinical outcomes. Methods In a prospective, multicentre, open-label, parallel-group controlled trial, 95 patients aged 18 to 65 years old, undergoing de novo heart transplantation were centrally randomised to receive either a low (130 Results At 12 months, the mean (± SD) creatinine value was 120.7 μmol/L (± 35.8) in the low-dose group and 132.3 μmol/L (± 49.1) in the standard-dose group (P = 0.162). Post hoc analyses suggested that patients with higher creatinine levels at baseline benefited significantly from the lower Cyclosporine A target. The number of patients with at least one rejection episode was not significantly different but one patient in the low-dose group and six in the standard-dose group required dialysis. Conclusions In patients with de novo cardiac transplantation, early Cyclosporine A dose reduction was not associated with renal benefit at 12 months. However, the strategy may benefit patients with high creatinine levels before transplantation. Trial registration ClinicalTrials.gov NCT00159159
- Published
- 2012
- Full Text
- View/download PDF
153. Individual patient data meta-analysis of survival data using Poisson regression models
- Author
-
Crowther Michael J, Riley Richard D, Staessen Jan A, Wang Jiguang, Gueyffier Francois, and Lambert Paul C
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background An Individual Patient Data (IPD) meta-analysis is often considered the gold-standard for synthesising survival data from clinical trials. An IPD meta-analysis can be achieved by either a two-stage or a one-stage approach, depending on whether the trials are analysed separately or simultaneously. A range of one-stage hierarchical Cox models have been previously proposed, but these are known to be computationally intensive and are not currently available in all standard statistical software. We describe an alternative approach using Poisson based Generalised Linear Models (GLMs). Methods We illustrate, through application and simulation, the Poisson approach both classically and in a Bayesian framework, in two-stage and one-stage approaches. We outline the benefits of our one-stage approach through extension to modelling treatment-covariate interactions and non-proportional hazards. Ten trials of hypertension treatment, with all-cause death the outcome of interest, are used to apply and assess the approach. Results We show that the Poisson approach obtains almost identical estimates to the Cox model, is additionally computationally efficient and directly estimates the baseline hazard. Some downward bias is observed in classical estimates of the heterogeneity in the treatment effect, with improved performance from the Bayesian approach. Conclusion Our approach provides a highly flexible and computationally efficient framework, available in all standard statistical software, to the investigation of not only heterogeneity, but the presence of non-proportional hazards and treatment effect modifiers.
- Published
- 2012
- Full Text
- View/download PDF
154. Standard requirements for GCP-compliant data management in multinational clinical trials
- Author
-
McPherson Gladys, Wittenberg Michael, Schade-Brittinger Carmen, Salas Nader, Lauritsen Jens, Canham Steve, Kuchinke Wolfgang, Ohmann Christian, McCourt John, Gueyffier Francois, Lorimer Andrea, and Torres Ferràn
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background A recent survey has shown that data management in clinical trials performed by academic trial units still faces many difficulties (e.g. heterogeneity of software products, deficits in quality management, limited human and financial resources and the complexity of running a local computer centre). Unfortunately, no specific, practical and open standard for both GCP-compliant data management and the underlying IT-infrastructure is available to improve the situation. For that reason the "Working Group on Data Centres" of the European Clinical Research Infrastructures Network (ECRIN) has developed a standard specifying the requirements for high quality GCP-compliant data management in multinational clinical trials. Methods International, European and national regulations and guidelines relevant to GCP, data security and IT infrastructures, as well as ECRIN documents produced previously, were evaluated to provide a starting point for the development of standard requirements. The requirements were produced by expert consensus of the ECRIN Working group on Data Centres, using a structured and standardised process. The requirements were divided into two main parts: an IT part covering standards for the underlying IT infrastructure and computer systems in general, and a Data Management (DM) part covering requirements for data management applications in clinical trials. Results The standard developed includes 115 IT requirements, split into 15 separate sections, 107 DM requirements (in 12 sections) and 13 other requirements (2 sections). Sections IT01 to IT05 deal with the basic IT infrastructure while IT06 and IT07 cover validation and local software development. IT08 to IT015 concern the aspects of IT systems that directly support clinical trial management. Sections DM01 to DM03 cover the implementation of a specific clinical data management application, i.e. for a specific trial, whilst DM04 to DM12 address the data management of trials across the unit. Section IN01 is dedicated to international aspects and ST01 to the competence of a trials unit's staff. Conclusions The standard is intended to provide an open and widely used set of requirements for GCP-compliant data management, particularly in academic trial units. It is the intention that ECRIN will use these requirements as the basis for the certification of ECRIN data centres.
- Published
- 2011
- Full Text
- View/download PDF
155. Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres
- Author
-
Doran Peter, Cooney Margaret, Gaynor Siobhan, Voko Zoltán, Wittenberg Michael, Schade-Brittinger Carmen, Leizorovicz Alan, Gueyffier Francois, Lauritsen Jens, Salas Nader, Yang Qin, Ohmann Christian, Kuchinke Wolfgang, Maggioni Aldo, Lorimer Andrea, Torres Ferràn, McPherson Gladys, Charwill Jim, Hellström Mats, and Lejeune Stéphane
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background The use of Clinical Data Management Systems (CDMS) has become essential in clinical trials to handle the increasing amount of data that must be collected and analyzed. With a CDMS trial data are captured at investigator sites with "electronic Case Report Forms". Although more and more of these electronic data management systems are used in academic research centres an overview of CDMS products and of available data management and quality management resources for academic clinical trials in Europe is missing. Methods The ECRIN (European Clinical Research Infrastructure Network) data management working group conducted a two-part standardized survey on data management, software tools, and quality management for clinical trials. The questionnaires were answered by nearly 80 centres/units (with an overall response rate of 47% and 43%) from 12 European countries and EORTC. Results Our survey shows that about 90% of centres have a CDMS in routine use. Of these CDMS nearly 50% are commercial systems; Open Source solutions don't play a major role. In general, solutions used for clinical data management are very heterogeneous: 20 different commercial CDMS products (7 Open Source solutions) in addition to 17/18 proprietary systems are in use. The most widely employed CDMS products are MACRO™ and Capture System™, followed by solutions that are used in at least 3 centres: eResearch Network™, CleanWeb™, GCP Base™ and SAS™. Although quality management systems for data management are in place in most centres/units, there exist some deficits in the area of system validation. Conclusions Because the considerable heterogeneity of data management software solutions may be a hindrance to cooperation based on trial data exchange, standards like CDISC (Clinical Data Interchange Standard Consortium) should be implemented more widely. In a heterogeneous environment the use of data standards can simplify data exchange, increase the quality of data and prepare centres for new developments (e.g. the use of EHR for clinical research). Because data management and the use of electronic data capture systems in clinical trials are characterized by the impact of regulations and guidelines, ethical concerns are discussed. In this context quality management becomes an important part of compliant data management. To address these issues ECRIN will establish certified data centres to support electronic data management and associated compliance needs of clinical trial centres in Europe.
- Published
- 2010
- Full Text
- View/download PDF
156. CAPPP trial. Captopril Prevention Project.
- Author
-
Gueyffier, F, Boissel, J P, and Plouin, P F
- Subjects
- *
ACE inhibitors , *CAPTOPRIL , *ANTIHYPERTENSIVE agents , *CEREBROVASCULAR disease , *HYPERTENSION , *DISEASE complications , *THERAPEUTICS - Published
- 1999
- Full Text
- View/download PDF
157. Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres.
- Author
-
Kuchinke W, Ohmann C, Yang Q, Salas N, Lauritsen J, Gueyffier F, Leizorovicz A, Schade-Brittinger C, Wittenberg M, Voko Z, Gaynor S, Cooney M, Doran P, Maggioni A, Lorimer A, Torres F, McPherson G, Charwill J, Hellström M, and Lejeune S
- Abstract
Background: The use of Clinical Data Management Systems (CDMS) has become essential in clinical trials to handle the increasing amount of data that must be collected and analyzed. With a CDMS trial data are captured at investigator sites with "electronic Case Report Forms". Although more and more of these electronic data management systems are used in academic research centres an overview of CDMS products and of available data management and quality management resources for academic clinical trials in Europe is missing.Methods: The ECRIN (European Clinical Research Infrastructure Network) data management working group conducted a two-part standardized survey on data management, software tools, and quality management for clinical trials. The questionnaires were answered by nearly 80 centres/units (with an overall response rate of 47% and 43%) from 12 European countries and EORTC.Results: Our survey shows that about 90% of centres have a CDMS in routine use. Of these CDMS nearly 50% are commercial systems; Open Source solutions don't play a major role. In general, solutions used for clinical data management are very heterogeneous: 20 different commercial CDMS products (7 Open Source solutions) in addition to 17/18 proprietary systems are in use. The most widely employed CDMS products are MACRO and Capture System, followed by solutions that are used in at least 3 centres: eResearch Network, CleanWeb, GCP Base and SAS. Although quality management systems for data management are in place in most centres/units, there exist some deficits in the area of system validation.Conclusions: Because the considerable heterogeneity of data management software solutions may be a hindrance to cooperation based on trial data exchange, standards like CDISC (Clinical Data Interchange Standard Consortium) should be implemented more widely. In a heterogeneous environment the use of data standards can simplify data exchange, increase the quality of data and prepare centres for new developments (e.g. the use of EHR for clinical research). Because data management and the use of electronic data capture systems in clinical trials are characterized by the impact of regulations and guidelines, ethical concerns are discussed. In this context quality management becomes an important part of compliant data management. To address these issues ECRIN will establish certified data centres to support electronic data management and associated compliance needs of clinical trial centres in Europe. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
158. Mortality in Diabetic Patents Unchanged by Treating Hypertension.
- Author
-
Lievre, M., Gueyffier, F., and Ekbom, T.
- Subjects
- *
DIURETICS , *THERAPEUTICS , *HYPERTENSION , *TREATMENT of diabetes , *DRUG efficacy - Abstract
Focuses on a study which reviewed the effectiveness of diuretic or Β-blocker-based treatment of hypertension in diabetic patients. Methodology; Results; Conclusion.
- Published
- 2000
159. Efficacy of diuretics and ß-blockers in diabetic hypertensive patients: results from a meta-analysis.
- Author
-
Lièvre M, Gueyffier F, Ekbom T, Fagard R, Cutler J, Schron E, Marre M, and Boissel J
- Abstract
OBJECTIVE: To review the effectiveness of diuretic or beta-blocker-based treatment of hypertension in diabetic patients. RESEARCH DESIGN AND METHODS: A meta-analysis on individual patient data was performed on four trials of the treatment of hxpertension in which diabetic patients were included and treated with first-line diuretics or beta-blockers. The main outcomes were the relative risk of death, fatal or nonfatal stroke, fatal or nonfatal coronary events, and major cardiovascular events. RESULTS: There were 92 diabetic patients who received first-line beta-blockers and 1,008 who received diuretics. In the control groups, diabetic patients had nearly twice the risk of any outcome when compared with nondiabetic patients. The same blood pressure reduction was achieved under treatment in the diabetic and nondiabetic patients, except for systolic pressure, which decreased more in the nondiabetic patients at 1 year. In the 15,843 nondiabetic patients, the risk of all four outcomes was reduced significantly in the treated group. In the 2,254 diabetic patients, the risk reduction was significant only for fatal and nonfatal stroke (36%, P = 0.011) and major cardiovascular events (20%, P = 0.032), but not for death (5%, P = 0.65) and fatal or nonfatal coronary events (15%, P = 0.23). However, no heterogeneity was detected between diabetic patients and nondiabetic patients for any outcome. The numbers of outcomes avoided for 1,000 patients treated for 5 years were higher in diabetic patients (e.g., 38 major cardiovascular events) than with nondiabetic patients (e.g., 28 major cardiovascular events). CONCLUSIONS: These results show that hypertensive diabetic patients benefit from first-line treatment with diuretics. No conclusion can be drawn for beta-blockers, owing to the small sample size. [ABSTRACT FROM AUTHOR]
- Published
- 2000
160. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials.
- Author
-
Staessen JA, Gasowski J, Wang JG, Thijs L, Hond ED, Boissel J, Coope J, Ekbom T, Gueyffier F, Liu L, Kerlikowske K, Pocock S, Fagard RH, Staessen, J A, Gasowski, J, Wang, J G, Thijs, L, Den Hond, E, Boissel, J P, and Coope, J
- Abstract
Background: Previous meta-analysis of outcome trials in hypertension have not specifically focused on isolated systolic hypertension or they have explained treatment benefit mainly in function of the achieved diastolic blood pressure reduction. We therefore undertook a quantitative overview of the trials to further evaluate the risks associated with systolic blood pressure in treated and untreated older patients with isolated systolic hypertensionMethods: Patients were 60 years old or more. Systolic blood pressure was 160 mm Hg or greater and diastolic blood pressure was less than 95 mm Hg. We used non-parametric methods and Cox regression to model the risks associated with blood pressure and to correct for regression dilution bias. We calculated pooled effects of treatment from stratified 2 x 2 contingency tables after application of Zelen's test of heterogeneity.Findings: In eight trials 15 693 patients with isolated systolic hypertension were followed up for 3.8 years (median). After correction for regression dilution bias, sex, age, and diastolic blood pressure, the relative hazard rates associated with a 10 mm Hg higher initial systolic blood pressure were 1.26 (p=0.0001) for total mortality, 1.22 (p=0.02) for stroke, but only 1.07 (p=0.37) for coronary events. Independent of systolic blood pressure, diastolic blood pressure was inversely correlated with total mortality, highlighting the role of pulse pressure as risk factor. Active treatment reduced total mortality by 13% (95% CI 2-22, p=0.02), cardiovascular mortality by 18%, all cardiovascular complications by 26%, stroke by 30%, and coronary events by 23%. The number of patients to treat for 5 years to prevent one major cardiovascular event was lower in men (18 vs 38), at or above age 70 (19 vs 39), and in patients with previous cardiovascular complications (16 vs 37).Interpretation: Drug treatment is justified in older patients with isolated systolic hypertension whose systolic blood pressure is 160 mm Hg or higher. Absolute benefit is larger in men, in patients aged 70 or more and in those with previous cardiovascular complications or wider pulse pressure. Treatment prevented stroke more effectively than coronary events. However, the absence of a relation between coronary events and systolic blood pressure in untreated patients suggests that the coronary protection may have been underestimated. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
161. Consistency of Safety and Efficacy of New Oral Anticoagulants across Subgroups of Patients with Atrial Fibrillation
- Author
-
Cyrielle Gremillet, Silvy Laporte, Céline Chapelle, Denis Vital-Durand, Laurent Bertoletti, Jean-Christophe Lega, Michel Cucherat, Patrick Mismetti, Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Meta-Embol Group, Laporte, S., Mismetti, P., Zufferey, P., Couturaud, F., Cucherat, M., Gueyffier, F., Leizorovicz, A., Meyer, G., Samama, CM., Steg, G., Albaladejo, P., Bertoletti, L., Chapelle, C., Garnier, P., Labruyère, C., Mottet, N., Girard, P., Marret, E., Parent, F., Rosencher, N., Lega, JC., Nony, P., and Wahl, D.
- Subjects
medicine.medical_specialty ,Clinical Research Design ,Epidemiology ,Cerebrovascular Diseases ,[SDV]Life Sciences [q-bio] ,Administration, Oral ,lcsh:Medicine ,Arrhythmias ,Cardiovascular ,Cardiovascular Pharmacology ,Dabigatran ,Internal medicine ,Diabetes mellitus ,Atrial Fibrillation ,Humans ,Medicine ,lcsh:Science ,Stroke ,Cardiovascular Disease Epidemiology ,Ischemic Stroke ,Randomized Controlled Trials as Topic ,Heart Failure ,Anticoagulants/administration & dosage ,Anticoagulants/adverse effects ,Atrial Fibrillation/drug therapy ,Clinical Trials, Phase III as Topic/methods ,Randomized Controlled Trials as Topic/methods ,Safety ,Rivaroxaban ,Multidisciplinary ,business.industry ,lcsh:R ,Warfarin ,Anticoagulants ,Atrial fibrillation ,medicine.disease ,3. Good health ,Surgery ,Neurology ,Clinical Trials, Phase III as Topic ,Heart failure ,Apixaban ,lcsh:Q ,Meta-Analyses ,business ,Research Article ,medicine.drug - Abstract
AIMS: The well-known limitations of vitamin K antagonists (VKA) led to development of new oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta-analysis was to determine the consistency of treatment effects of NOAC irrespective of age, comorbidities, or prior VKA exposure. METHODS AND RESULTS: All randomized, controlled phase III trials comparing NOAC to VKA up to October 2012 were eligible provided their results (stroke/systemic embolism (SSE) and major bleeding (MB)) were reported according to age (≤ or >75 years), renal function, CHADS2 score, presence of diabetes mellitus or heart failure, prior VKA use or previous cerebrovascular events. Interactions were considered significant at p
- Published
- 2014
162. CO-05: The first risk score for sudden death prediction in primary prevention patients.
- Author
-
Le, H., Subtil, F., Cerou, M., Al Gobari, M., Fall, M., Henin, E., Janiaud, P., Berrima, A., Girard, M., Erpeldinger, S., Kaissai, B., Chevalier, P., and Gueyffier, F.
- Subjects
- *
CARDIOVASCULAR diseases risk factors , *CORONARY heart disease risk factors , *HYPERTENSION , *PRIMARY care , *SUDDEN death , *SYMPTOMS - Abstract
Background Sudden death defined as a death within 1h from the onset of symptom, is a common cardiovascular accident, even more frequent than fatal myocardial infarction. Up to now, DUKE is the only sudden death risk predictor and it was designed specifically for patients of high coronary risk. We constructed here the first sudden death risk score for primary prevention, developed in patients with hypertension and type 2 diabetes. Methods We used the Cox model to build this risk score on R (version 3.2.2) based on 30 560 individual data from seven randomized controlled trials (six of INDANA database in hypertension & one in type 2 diabetes Diahhycab). Results There was no treatment effect and no interaction between treatment and other covariates on the risk of sudden death. This allowed us to develop the model on both treatment/placebo groups. We identified seven risk factors of sudden death : age, sex (male), smoking, cholesterolemia, systolic blood pressure, baseline of type 2 diabetes and history of myocardial infarction. The discrimination performance of the tool was fair (area under the receiver operating characteristic curve (AUC) was about 70%). Conclusions Our work provides the first risk score for sudden death prediction in primary prevention patients. This risk score, in particular in hypertension and type 2 diabetes could help stratify patients in order to optimize preventive therapeutic strategies in primary prevention. Further research on sudden death is required to better prevent this highly frequent form of death. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
163. Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.
- Author
-
Esparragosa Vazquez I, Sanson M, Chinot OL, Fontanilles M, Rivoirard R, Thomas-Maisonneuve L, Cartalat S, Tabouret E, Appay R, Bonneville-Levard A, Darlix A, Meyronet D, Barritault M, Gueyffier F, Remontet L, Maucort-Boulch D, Honnorat J, Dehais C, and Ducray F
- Abstract
Background: Based on preclinical studies showing that IDH-mutant (IDHm) gliomas could be vulnerable to PARP inhibition we launched a multicenter phase 2 study to test the efficacy of olaparib monotherapy in this population., Methods: Adults with recurrent IDHm high-grade gliomas (HGGs) after radiotherapy and at least one line of alkylating chemotherapy were enrolled. The primary endpoint was a 6-month progression-free survival rate (PFS-6) according to response assessment in neuro-oncology criteria. Pre-defined threshold for study success was a PFS-6 of at least 50%., Results: Thirty-five patients with recurrent IDHm HGGs were enrolled, 77% at ≥ 2nd recurrence. Median time since diagnosis and radiotherapy were 7.5 years and 33 months, respectively. PFS-6 was 31.4% (95% CI [16.9; 49.3%]). Two patients (6%) had an objective response and 14 patients (40%) had a stable disease as their best response. Median PFS and median overall survival were 2.05 and 15.9 months, respectively. Oligodendrogliomas (1p/19q codeleted) had a higher PFS-6 (53.4% vs. 15.7%, P = .05) than astrocytomas while an initial diagnosis of grade 4 astrocytoma tended to be associated with a lower PFS-6 compared to grade 2/3 gliomas (0% vs 31.4%, P = .16). A grade 2 or 3 treatment-related adverse event was observed in 15 patients (43%) and 5 patients (14%), respectively. No patient definitively discontinued treatment due to side effects., Conclusions: Although it did not meet its primary endpoint, the present study shows that in this heavily pretreated population, olaparib monotherapy was well tolerated and resulted in some activity, supporting further PARP inhibitors evaluation in IDHm HGGs, especially in oligodendrogliomas., Competing Interests: I.E.: none. M.S.: none. O.C.: none. M.F.: research purposes from Servier company, benefits for interventions from Seagen and Novocure, and payment of congress fees from Gilead and Pfizer. R.R.: Advisory board (Daiichi Sankyo, Lilly), travel grants (Amgen, Astra Zeneca, Bayer HealthCare SAS, Daiichi Sankyo, Lilly, MSD France, Novartis Pharma SAS, Pfizer, Roche). S.C.: MSD (travel grant). E.T.: Gliocure, Leo Pharma (advisory board), Leo Pharma (research grant), Novocure, Servier (symposium. A.B-L.: none. A. D.: Servier, Novocure (advisory board), Servier (travel grants). D.M.: none. M.B.: none. F.G.: none. L.R.: none. D.M-B.: none. J.H.: Novocure (travel grants, advisory board). C.D.: none. F.D.: Servier, Novocure (advisory board, symposium)., (© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
- Published
- 2024
- Full Text
- View/download PDF
164. Estimating individualized treatment effects using an individual participant data meta-analysis.
- Author
-
Bouvier F, Chaimani A, Peyrot E, Gueyffier F, Grenet G, and Porcher R
- Subjects
- Humans, Computer Simulation, Randomized Controlled Trials as Topic, Models, Statistical
- Abstract
Background: One key aspect of personalized medicine is to identify individuals who benefit from an intervention. Some approaches have been developed to estimate individualized treatment effects (ITE) with a single randomized control trial (RCT) or observational data, but they are often underpowered for the ITE estimation. Using individual participant data meta-analyses (IPD-MA) might solve this problem. Few studies have investigated how to develop risk prediction models with IPD-MA, and it remains unclear how to combine those methods with approaches used for ITE estimation. In this article, we compared different approaches using both simulated and real data with binary and time-to-event outcomes to estimate the individualized treatment effects from an IPD-MA in a one-stage approach., Methods: We compared five one-stage models: naive model (NA), random intercept (RI), stratified intercept (SI), rank-1 (R1), and fully stratified (FS), built with two different strategies, the S-learner and the T-learner constructed with a Monte Carlo simulation study in which we explored different scenarios with a binary or a time-to-event outcome. To evaluate the performance of the models, we used the c-statistic for benefit, the calibration of predictions, and the mean squared error. The different models were also used on the INDANA IPD-MA, comparing an anti-hypertensive treatment to no treatment or placebo ( N = 40 237 , 836 events)., Results: Simulation results showed that using the S-learner led to better ITE estimation performances for both binary and time-to-event outcomes. None of the risk models stand out and had significantly better results. For the INDANA dataset with a binary outcome, the naive and the random intercept models had the best performances., Conclusions: For the choice of the strategy, using interactions with treatment (the S-learner) is preferable. For the choice of the method, no approach is better than the other., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
165. Rapid access to innovative medicinal products while ensuring relevant health technology assessment. Position of the French National Authority for Health.
- Author
-
Vanier A, Fernandez J, Kelley S, Alter L, Semenzato P, Alberti C, Chevret S, Costagliola D, Cucherat M, Falissard B, Gueyffier F, Lambert J, Lengliné E, Locher C, Naudet F, Porcher R, Thiébaut R, Vray M, Zohar S, Cochat P, and Le Guludec D
- Subjects
- Humans, Technology Assessment, Biomedical, Drug Industry
- Abstract
Competing Interests: Competing interests: DC reports an HIV grant from Janssen (2019-2020), personal fees from Gilead (2020) and Pfizer (2022) for lectures outside the submitted work. RT has been the coordinator of the IMI2 EBOVAC2 project in collaboration with Janssen (2014-2021). Other authors have no competing interests to disclose.
- Published
- 2024
- Full Text
- View/download PDF
166. Diabetes, periodontitis, and cardiovascular disease: towards equity in diabetes care.
- Author
-
Serón C, Olivero P, Flores N, Cruzat B, Ahumada F, Gueyffier F, and Marchant I
- Subjects
- Humans, Quality of Life, Diabetes Mellitus, Type 2 therapy, Cardiovascular Diseases therapy, Periodontitis epidemiology, Periodontitis therapy, Epidemics
- Abstract
Type 2 diabetes and its associated cardiovascular risk is an escalating epidemic that represents a significant public health burden due to increased morbidity and mortality, disproportionately affecting disadvantaged communities. Poor glycaemic control exacerbates this burden by increasing retinal, renal, and cardiac damage and raising healthcare costs. This predicament underscores the urgent need for research into cost-effective approaches to preventing diabetes complications. An important but often overlooked strategy to improve metabolic control in diabetic patients is the treatment of periodontitis. Our aim is to assess whether the inclusion of periodontitis treatment in diabetes management strategies can effectively improve metabolic control, and to advocate for its inclusion from an equity perspective. We conducted a comprehensive review of the literature from 2000 to 2023. We analyzed the pathophysiological links between periodontitis, diabetes, and atherosclerotic cardiovascular disease, all of which have inflammation as a central component. We also examined the inequalities in health care spending in this context. Our findings suggest that incorporating routine screening and treatment of periodontitis into national health programs, with coordinated efforts between physicians and dentists, is a cost-effective measure to improve metabolic control, reduce complications and improve the overall quality of life of people with diabetes., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Serón, Olivero, Flores, Cruzat, Ahumada, Gueyffier and Marchant.)
- Published
- 2023
- Full Text
- View/download PDF
167. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients presenting sepsis-induced immunosuppression: The GRID randomized controlled trial.
- Author
-
Vacheron CH, Lepape A, Venet F, Monneret G, Gueyffier F, Boutitie F, Vallin H, Schwebel C, Maucort-Boulch D, and Friggeri A
- Subjects
- Adult, Humans, Granulocyte-Macrophage Colony-Stimulating Factor therapeutic use, Immunosuppression Therapy, Immunocompromised Host, Shock, Septic drug therapy, Sepsis
- Abstract
Purpose: Septic shock is associated in some patients with a profound immunosuppression. We hypothesized that GM-CSF would reduce the occurrence of ICU-acquired infections in immunosuppressed septic patients., Methods: Randomized double-blind trial conducted between 2015 and 2018. Adult patients, admitted to ICU, with severe sepsis or septic shock presenting with sepsis-induced immunosuppression defined by mHLA-DR < 8000 ABC (antibodies bound per cell) at day 3 were included. Patients were randomized to receive GM-CSF 125 μg/m
2 or placebo for 5 days at a 1:1 ratio. The primary outcome was the difference in the number of patients presenting≥1 ICU-acquired infection at day 28 or ICU discharge., Results: The study was prematurely stopped because of insufficient recruitment. A total of 98 patients were included, 54 in the intervention group and 44 in the placebo group. The two groups were similar except for a higher body mass index and McCabe score in the intervention group. No significant difference was observed between groups regarding ICU-acquired infection (11% vs 11%, p = 1.000), 28-day mortality (24% vs 27%,p = 0.900), or the number or localization of the ICU infections., Conclusion: GM-CSF had no effect on the prevention of ICU-acquired infection in sepsis immunosuppression, but any conclusion is limited by the early termination of the study leading to low number of included patients., Competing Interests: Declaration of Competing Interest None., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
168. [Does aspirin have a place in primary cardiovascular prevention by the polypill ? Simulation study on a realistic virtual population].
- Author
-
Fall M, Grenet G, Le HH, Kassaï B, Lega JC, Boussageon R, Mainbourg S, Marchant I, Gafsi J, Dieye AM, and Gueyffier F
- Subjects
- Male, Humans, Female, Adult, Middle Aged, Aged, Aspirin therapeutic use, Hemorrhage, Platelet Aggregation Inhibitors therapeutic use, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Myocardial Infarction drug therapy, Stroke prevention & control, Diabetes Mellitus drug therapy, Hypertension drug therapy, Hypertension epidemiology
- Abstract
Background: The polypill strategy could become widely accepted in cardiovascular prevention due to reduced costs and its simplicity, which promote compliance. Aspirin is often included as a component of the polypill for primary prevention, but three powerful recent trials failed to show any favorable net benefit even in high-risk subgroups. Our objective is to estimate the net benefit associated with aspirin in primary cardiovascular prevention., Methods: We simulated the impact of different polypill compositions combining pravastatin, ramipril, hydrochlorothiazide, with or without aspirin, on a realistic French virtual population between 35 and 65 years old. We assessed how this impact on myocardial infarction and stroke varied according to gender, diabetes, and arterial hypertension. We identified the subgroup of individuals whose specific benefit from aspirin was greater than twice the risk of serious bleeding it induced., Results: The absolute benefit associated with aspirin was reduced by co-prescriptions. No subgroup of women benefited from aspirin, and the subgroup of women with a clear net benefit represented 128 women out of 529,421. Men at high risk of cardiovascular death, or with diabetes and hypertension, had a benefit from aspirin exceeding the risk of bleeding induced, but this risk represented more than half of the benefit. No subgroup analyzed did show a benefit greater than twice the risk of bleeding. The proportion of men whose expected benefit from aspirin was greater than twice the risk of bleeding represented 3% of all men. An optimal polypill strategy in primary prevention between the ages of 35 and 65, combining three drugs but not aspirin, can hope to save two out of three strokes and more than one out of two myocardial infarctions. It would prevent a major cardiovascular accident every 16 to 193 individuals treated according to the subgroups considered., Conclusion: Until proven otherwise, aspirin has only a limited place in individuals between 35 and 65 years without a cardiovascular history. We showed how simulating therapeutic strategies on a realistic virtual population could be used for best applying available evidence., (Copyright © 2023 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
169. [ECRIN standard requirements for good clinical practices-compliant data management in multinational clinical trials].
- Author
-
Cornu C, Donche A, Coffre C, Le Gouge A, Rym B, Vaugier I, Barbot F, Leizorovicz A, Juge N, Giraud C, Gueyffier F, Félin A, Mura T, Chevassus H, and Binquet C
- Abstract
Context: Clinical studies involve an increasing amount of data collection and management. However, there is no specific quality standard sufficiently practical, in free access, and open for data management and the underlying IT-infrastructure in academic units. European Clinical Research Infrastructures Network (ECRIN) published standard requirements for certified data management units. We present a French version of these standards., Methods: A group of experts produced the standards, by consensus. The first version was revised after two pilot audits for data centre certification were performed., Results: The revised version includes 21 lists of five to ten standards, in three groups: information technologies, data management (DM) and "general"., Conclusions: These standards offer a clear description of DM and IT requirements for clinical studies. Initially created for ECRIN certification purposes, they offer a very useful reference for academic DM structures., (Copyright © 2016. Published by Elsevier Masson SAS.)
- Published
- 2023
- Full Text
- View/download PDF
170. Project rebuild the evidence base (REB): A method to interpret randomised clinical trials and their meta-analysis to present solid benefit-risk assessments to patients.
- Author
-
Boussageon R, Blanchard C, Charuel E, Menini T, Pereira B, Naudet F, Kassai B, Gueyffier F, Cucherat M, and Vaillant-Roussel H
- Abstract
Evidence-based medicine is the cornerstone of shared-decision making in healthcare today. The public deserves clear, transparent and trust-worthy information on drug efficacy. Yet today, many drugs are prescribed and used without solid evidence of efficacy. Clinical trials and randomised clinical trials (RCTs) are the best method to evaluate drug efficacy and side effects. In a shared medical decision-making approach, general practitioners need drug assessment based on patient-important outcomes. The aim of project rebuild the evidence base (REB) is to bridge the gap between the data needed in clinical practice and the data available from clinical research. The drugs will be assessed on clinical patient important outcomes and for a population. Using the Cochrane tools, we propose to analyse for each population and outcome: 1) a meta-analysis based on RCTs with a low risk of bias overall; 2) an evaluation of results of confirmatory RCTs; 3) a statistical analysis of heterrogeneity between RCTs and 4) an analysis of publication bias. Depending on the results of these analyses, the evidence will be categorized in 4 different levels: firm evidence, evidence (to be confirmed), signal or absence of evidence. Project REB proposes a method for reading and interpreting RCTs and their meta-analysis to produce quality data for general practitioners to focus on risk-benefit assessment in the interest of patients. If this data does not exist, it could enable clinical research to better its aim., (Copyright © 2022 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
171. Pharmacokinetic/pharmacodynamic model of a methionine starvation based anti-cancer drug.
- Author
-
Eymard N, Bessonov N, Volpert V, Kurbatova P, Gueyffier F, and Nony P
- Subjects
- Humans, Animals, Mice, Methionine metabolism, Methionine therapeutic use, Racemethionine, Erythrocytes metabolism, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacokinetics, Neoplasms drug therapy
- Abstract
A new therapeutic approach against cancer is developed by the firm Erytech. This approach is based on starved cancer cells of an amino acid essential to their growth (the L-methionine). The depletion of plasma methionine level can be induced by an enzyme, the methionine-γ-lyase. The new therapeutic formulation is a suspension of erythrocytes encapsulating the activated enzyme. Our work reproduces a preclinical trial of a new anti-cancer drug with a mathematical model and numerical simulations in order to replace animal experiments and to have a deeper insight on the underlying processes. With a combination of a pharmacokinetic/pharmacodynamic model for the enzyme, substrate, and co-factor with a hybrid model for tumor, we develop a "global model" that can be calibrated to simulate different human cancer cell lines. The hybrid model includes a system of ordinary differential equations for the intracellular concentrations, partial differential equations for the concentrations of nutrients and drugs in the extracellular matrix, and individual based model for cancer cells. This model describes cell motion, division, differentiation, and death determined by the intracellular concentrations. The models are developed on the basis of experiments in mice carried out by Erytech. Parameters of the pharmacokinetics model were determined by fitting a part of experimental data on the concentration of methionine in blood. Remaining experimental protocols effectuated by Erytech were used to validate the model. The validated PK model allowed the investigation of pharmacodynamics of cell populations. Numerical simulations with the global model show cell synchronization and proliferation arrest due to treatment similar to the available experiments. Thus, computer modeling confirms a possible effect of treatment based on the decrease of methionine concentration. The main goal of the study is the development of an integrated pharmacokinetic/pharmacodynamic model for encapsulated methioninase and of a mathematical model of tumor growth/regression in order to determine the kinetics of L-methionine depletion after co-administration of Erymet product and Pyridoxine., (© 2023. International Federation for Medical and Biological Engineering.)
- Published
- 2023
- Full Text
- View/download PDF
172. Barriers and Facilitators to the Use of Clinical Decision Support Systems in Primary Care: A Mixed-Methods Systematic Review.
- Author
-
Meunier PY, Raynaud C, Guimaraes E, Gueyffier F, and Letrilliart L
- Subjects
- Humans, Health Personnel, Technology, Primary Health Care, Decision Support Systems, Clinical
- Abstract
Purpose: To identify and quantify the barriers and facilitators to the use of clinical decision support systems (CDSSs) by primary care professionals (PCPs)., Methods: A mixed-methods systematic review was conducted using a sequential synthesis design. PubMed/MEDLINE, PsycInfo, Embase, CINAHL, and the Cochrane library were searched in July 2021. Studies that evaluated CDSSs providing recommendations to PCPs and intended for use during a consultation were included. We excluded CDSSs used only by patients, described as concepts or prototypes, used with simulated cases, and decision supports not considered as CDSSs. A framework synthesis was performed according to the HOT-fit framework (Human, Organizational, Technology, Net Benefits), then a quantitative synthesis evaluated the impact of the HOT-fit categories on CDSS use., Results: A total of 48 studies evaluating 45 CDSSs were included, and 186 main barriers or facilitators were identified. Qualitatively, barriers and facilitators were classified as human (eg, perceived usefulness), organizational (eg, disruption of usual workflow), and technological (eg, CDSS user-friendliness), with explanatory elements. The greatest barrier to using CDSSs was an increased workload. Quantitatively, the human and organizational factors had negative impacts on CDSS use, whereas the technological factor had a neutral impact and the net benefits dimension a positive impact., Conclusions: Our findings emphasize the need for CDSS developers to better address human and organizational issues, in addition to technological challenges. We inferred core CDSS features covering these 3 factors, expected to improve their usability in primary care., (© 2023 Annals of Family Medicine, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
173. Population designations in biomedical research: Limitations and perspectives.
- Author
-
Gombault C, Grenet G, Segurel L, Duret L, Gueyffier F, Cathébras P, Pontier D, Mainbourg S, Sanchez-Mazas A, and Lega JC
- Subjects
- Humans, Geography, Biomedical Research, Population Groups
- Abstract
In biomedical research, population differences are of central interest. Variations in the frequency and severity of diseases and in treatment effects among human subpopulation groups are common in many medical conditions. Unfortunately, the practices in terms of subpopulation labeling do not exhibit the level of rigor one would expect in biomedical research, especially when studying multifactorial diseases such as cancer or atherosclerosis. The reporting of population differences in clinical research is characterized by large disparities in practices, and fraught with methodological issues and inconsistencies. The actual designations such as "Black" or "Asian" refer to broad and heterogeneous groups, with a great discrepancy among countries. Moreover, the use of obsolete concepts such as "Caucasian" is unfortunate and imprecise. The use of adequate labeling to reflect the scientific hypothesis needs to be promoted. Furthermore, the use of "race/ethnicity" as a unique cause of human heterogeneity may distract from investigating other factors related to a medical condition, particularly if this label is employed as a proxy for cultural habits, diet, or environmental exposure. In addition, the wide range of opinions among researchers does not facilitate the attempts made for resolving this heterogeneity in labeling. "Race," "ethnicity," "ancestry," "geographical origin," and other similar concepts are saturated with meanings. Even if the feasibility of a global consensus on labeling seems difficult, geneticists, sociologists, anthropologists, and ethicists should help develop policies and practices for the biomedical field., (© 2022 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
174. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.
- Author
-
Marilly E, Cottin J, Cabrera N, Cornu C, Boussageon R, Moulin P, Lega JC, Gueyffier F, Cucherat M, and Grenet G
- Subjects
- Humans, Risk Assessment, Randomized Controlled Trials as Topic, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Diabetes Mellitus, Type 2 complications, Diabetic Ketoacidosis drug therapy, Heart Failure etiology, Kidney Failure, Chronic complications, Cardiovascular Diseases
- Abstract
Aims/hypothesis: Cardiovascular outcome trials (CVOTs) have demonstrated the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i). However, serious adverse drug reactions have been reported. The risk/benefit ratio of SGLT2i remains unquantified. We aimed to provide an estimation of their risk/benefit ratio in individuals with type 2 diabetes., Methods: We conducted a systematic review (MEDLINE, up to 14 September 2021) and meta-analysis. We included randomised CVOTs assessing SGLT2i in individuals with type 2 diabetes with or without other diseases. We used the Cochrane 'Risk of bias' assessment tool. The primary outcomes were overall mortality, major adverse cardiovascular events (MACE), hospitalisation for heart failure (HHF), end-stage renal disease (ESRD), amputation, diabetic ketoacidosis (DKA) and reported genital infections. For each outcome, we estimated the incidence rate ratio (IRR) with a 95% CI; we then computed the number of events expected spontaneously and with SGLT2i., Results: A total of 46,969 participants from five double-blind, placebo-controlled international trials (weighted mean follow-up 3.5 years) were included. The prevalence of previous CVD ranged from 40.6% to 99.2%. The definition of reported genital infections ranged from 'genital mycotic infection' to 'genital infections that led to discontinuation of the trial regimen or were considered to be serious adverse events'. The number of included studies for each outcomes was five. The use of SGLT2i decreased the risk of all-cause death (IRR 0.86 [95% CI 0.78, 0.95]), MACE (IRR 0.91 [95% CI 0.86, 0.96]), HHF (IRR 0.69 [95% CI 0.62, 0.76]) and ESRD (IRR 0.67 [95% CI 0.53, 0.84]), and increased the risk of DKA (IRR 2.59 [95% CI 1.57, 4.27]) and genital infection (IRR 3.50 [95% CI 3.09, 3.95]) but not of amputation (IRR 1.23 [95% CI 1.00, 1.51]). For 1000 individuals treated over 3.5 years, SGLT2i are expected, on average, to decrease the number of deaths from 70 to 61, to prevent nine MACE, 11 HHF and two cases of ESRD, while inducing two DKA occurrences and 36 genital infections; 778 individuals are expected to avoid all the following outcomes: MACE, HHF, ESRD, amputation, DKA and genital infection., Conclusions/interpretation: Our study is limited to aggregate data. In a population of individuals with type 2 diabetes and a high CVD risk, the cardiovascular and renal benefits of SGLT2i remain substantial despite the risk of DKA and even the hypothetical risk of amputation., Trial Registration: OSF Registries: https://doi.org/10.17605/OSF.IO/J3R7Y FUNDING: This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
175. Predicted Impacts of Booster, Immunity Decline, Vaccination Strategies, and Non-Pharmaceutical Interventions on COVID-19 Outcomes in France.
- Author
-
Pageaud S, Eyraud-Loisel A, Bertoglio JP, Bienvenüe A, Leboisne N, Pothier C, Rigotti C, Ponthus N, Gauchon R, Gueyffier F, Vanhems P, Iwaz J, Loisel S, Roy P, and On Behalf Of The CovDyn Group Covid Dynamics
- Abstract
The major economic and health consequences of COVID-19 called for various protective measures and mass vaccination campaigns. A previsional model was used to predict the future impacts of various measure combinations on COVID-19 mortality over a 400-day period in France. Calibrated on previous national hospitalization and mortality data, an agent-based epidemiological model was used to predict individual and combined effects of booster doses, vaccination of refractory adults, and vaccination of children, according to infection severity, immunity waning, and graded non-pharmaceutical interventions (NPIs). Assuming a 1.5 hospitalization hazard ratio and rapid immunity waning, booster doses would reduce COVID-19-related deaths by 50-70% with intensive NPIs and 93% with moderate NPIs. Vaccination of initially-refractory adults or children ≥5 years would half the number of deaths whatever the infection severity or degree of immunity waning. Assuming a 1.5 hospitalization hazard ratio, rapid immunity waning, moderate NPIs and booster doses, vaccinating children ≥12 years, ≥5 years, and ≥6 months would result in 6212, 3084, and 3018 deaths, respectively (vs. 87,552, 64,002, and 48,954 deaths without booster, respectively). In the same conditions, deaths would be 2696 if all adults and children ≥12 years were vaccinated and 2606 if all adults and children ≥6 months were vaccinated (vs. 11,404 and 3624 without booster, respectively). The model dealt successfully with single measures or complex combinations. It can help choosing them according to future epidemic features, vaccination extensions, and population immune status.
- Published
- 2022
- Full Text
- View/download PDF
176. Do drugs interact together in cardiovascular prevention? A meta-analysis of powerful or factorial randomized controlled trials.
- Author
-
Fall M, Le HH, Bouvier A, Louis C, Elias E, Yacoub K, Al-Gobari M, Grenet G, Seye M, Simeon G, Dieye AM, and Gueyffier F
- Subjects
- Humans, Randomized Controlled Trials as Topic, Antihypertensive Agents therapeutic use, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 prevention & control, Hypertension drug therapy, Hypertension epidemiology, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control
- Abstract
Aim of the Study: To explore whether preventive cardiovascular drugs (antihypertensive, antiplatelet, lipid lowering and hypoglycemic agents) interact together in cardiovascular prevention., Methods: We searched PubMed®, Web of science™, Embase and Cochrane library for powerful randomized placebo-controlled trials (>1000 patients). We explored whether drug effect on major vascular events changed according to cross-exposure to other drug classes or to cardiovascular risk factors (hypertension or type 2 diabetes), through a meta-analysis of relative odds ratio computed by trial subgroups. A significant interaction was suggested from confidence intervals of the ratio of odds ratios, when they excluded neutral value of 1., Results: In total, 14 trials with 178,398 patients were included. No significant interaction was observed between co-prescribed drugs or between these medications and type 2 diabetes/hypertension status., Conclusions: Our meta-analysis is the first one to evaluate drug-drug and drug-hypertension/type 2 diabetes status interactions in terms of cardiovascular risks: we did not observe any significant interaction. This indirectly reinforces the rationale of using several contrasted mechanisms to address cardiovascular prevention; and allows the combination effect prediction by a simple multiplication of their odds ratios. The limited availability of data reported or obtained from authors is a strong argument in favor of data sharing., (Copyright © 2022 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
177. Indirect Comparison of Glucocorticoid-Sparing Agents for Remission Maintenance in Giant Cell Arteritis: A Network Meta-analysis.
- Author
-
Mainbourg S, Tabary A, Cucherat M, Gueyffier F, Lobbes H, Aussedat M, Grenet G, Durieu I, Samson M, and Lega JC
- Subjects
- Adalimumab, Etanercept, Glucocorticoids therapeutic use, Humans, Infliximab, Network Meta-Analysis, Randomized Controlled Trials as Topic, Giant Cell Arteritis drug therapy, Methotrexate therapeutic use
- Abstract
Objective: To compare and rank the effect of glucocorticoid-sparing agents in giant cell arteritis (GCA), for which several drugs have been evaluated but with a benefit-risk balance that remains uncertain., Methods: The MEDLINE and Clinical Trials databases were searched up to November 2021; all randomized controlled trials investigating glucocorticoids in GCA were included. The glucocorticoid regimen was dichotomized into short (≤6 months) or prolonged (>6 months) use. Risk of relapse and safety were estimated using network meta-analysis with frequentist random effects models., Results: Of the 96 records screened, 8 trials were included (572 patients). The trials compared glucocorticoids and a sparing agent: tocilizumab (2 trials), oral methotrexate (3 trials), infliximab (1 trial), etanercept (1 trial), and adalimumab (1 trial). The pooled prevalence of GCA relapse was 52.6% (95% CI, 38.1 to 66.9). The risk of relapse was significantly lower with tocilizumab compared with methotrexate (relative risk [RR], 0.41; 95% CI, 0.17 to 0.97) and prolonged (RR, 0.41; 95% CI, 0.20 to 0.83) and short (RR, 0.32; 95% CI, 0.16 to 0.66) glucocorticoid use. The risk of relapse was not significantly different with methotrexate compared with short (RR, 0.79; 95% CI, 0.48 to 1.31) and prolonged (RR, 0.95; 95% CI, 0.31 to 2.89) glucocorticoid use. The frequency of serious adverse events and serious infection was comparable between the different drugs. The certainty of the evidence was low to very low., Conclusion: This meta-analysis suggests that tocilizumab may be superior to other sparing agents to prevent GCA relapse, but with a low to very low certainty of evidence, and that safety is comparable to the other drugs., Registration: The protocol of the meta-analysis is registered in the international prospective register of systematic reviews PROSPERO (https://www.crd.york.ac.uk/prospero/; registration CRD42020112387)., (Copyright © 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
178. How do they add up? The interaction between the placebo and treatment effect: A systematic review.
- Author
-
Boussageon R, Howick J, Baron R, Naudet F, Falissard B, Harika-Germaneau G, Wassouf I, Gueyffier F, Jaafari N, and Blanchard C
- Subjects
- Humans, Placebo Effect
- Abstract
Aim: The placebo effect and the specific effect are often thought to add up (additive model). Whether additivity holds can dramatically influence the external validity of a trial. This assumption of additivity was tested by Kleijnen et al in 1994 but the data produced since then have not been synthetized. In this review, we aimed to systematically review the literature to determine whether additivity held., Methods: We searched Medline and PsychInfo up to 10 January 2019. Studies using the balanced placebo design (BPD), testing two different strengths of placebos, were included. The presence of interaction was evaluated by comparing each group in the BPD with analysis of variance or covariance., Results: Thirty studies were included and the overall risk of bias was high: four found evidence of additivity and 16 studies found evidence of interaction (seven had evidence of positive additivity)., Conclusion: Evidence of additivity between placebo and specific features of treatments was rare in included studies. We suggest interventions for placebo-sensitive ailments should be tested in trials designed to take interactions seriously once an exploratory RCTs has proven their efficacy with sufficient internal validity., (© 2022 British Pharmacological Society.)
- Published
- 2022
- Full Text
- View/download PDF
179. Selected and simplified FDI criteria for assessment of restorations.
- Author
-
Maillet C, Decup F, Dantony E, Iwaz J, Chevalier C, Gueyffier F, Maucort-Boulch D, Grosgogeat B, and Le Clerc J
- Subjects
- Composite Resins, Dental Restoration Failure, Esthetics, Dental, Glass Ionomer Cements, Humans, Dental Caries, Dental Restoration, Permanent methods
- Abstract
Objectives: Assess the quality of dental restorations with simplified FDI criteria and examine its relationships with other general characteristics of restored teeth., Methods: The study involved 76 dentists from private and hospital practices. Assessments of successes and failures of previous restorations used a simplified rating with FDI criteria 3 to 8, 11, 12, and 14. The results were examined versus tooth location, number of restored surfaces, type of restoration, and filling material., Results: The dentists examined 4,612 dental restorations, of which 4,185 direct fillings mainly with resin composite materials (2,555). Of all restorations, 2,048 (44.4%) were considered as failures, of which 1,489 had one or two criteria for 'clinically unsatisfactory/poor restoration'. As simplified, the esthetic criterion 'color match' was the most frequent criterion for failure (912 cases). The rate of restoration failures was found associated with the number of surfaces restored and the use of glass-ionomer cement. Results are not comparable with others obtained with original FDI criteria., Conclusions: Assessing dental restorations with the original FDI criteria leads generally to much more failure statements than practitioners' decisions to reintervene. Though requiring some adjustment (e.g., regarding 'color match'), the simplified assessment proved convenient and amenable to standardization., Clinical Significance: Regardless of the type of practice, selecting, understanding, and optimal interpreting of FDI criteria for failure is essential to help practitioners faced with daily dilemmas of replacement vs. repair of failed dental restorations. Standardization of simplified criteria is desirable to help comparing research data., (Copyright © 2022. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
180. Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: A meta-analysis of randomised control-trials.
- Author
-
Sun S, Hisland L, Grenet G, Gueyffier F, Cornu C, Jaafari N, and Boussageon R
- Subjects
- Blood Glucose analysis, Glycemic Control, Humans, Proteinuria complications, Randomized Controlled Trials as Topic, Diabetes Mellitus, Type 2 complications, Diabetes Mellitus, Type 2 drug therapy, Macular Edema epidemiology, Macular Edema etiology
- Abstract
Objective: To re-assess the effect of tight glycaemic control on diabetic microvascular complications., Method: Meta-analysis and trial sequential analyses of randomised trials included in Hemmingsen et al that specifically assessed glycaemic control with a specific HbA
1c level targeted in the intervention group, and compared intensive glycaemic control versus standard glycaemic control., Results: Seven clinical trials that randomised 28,614 participants with type 2 diabetes (15,269 to intensive control and 13,345 to conventional control), including 3 sub-studies, were included. Strict control of blood glucose levels is associated with a reduction of retinopathy progression (RR=0.77, 95% CI: 0.66-0.89, I2 =33%), incidence or progression of macular oedema (RR=0.66, 95% CI: 0.40-0.99, I2 =0%), number of photocoagulations (RR=0.84, 95% CI: 0.73-0.97, I2 =0%), risk of microalbuminuria (RR=0.76, 95% CI: 0.64-0.9, I2 =76%) and risk of "macroalbuminuria or proteinuria" (RR=0.68, 95% CI: 0.55-0.85, I2 =36%)., Conclusion: This meta-analysis has shown that a tight control of blood glucose levels is associated with a decrease of specific microvascular complication of diabetes: photocoagulation, progression of diabetic retinopathy, incidence or progression of macular oedema, risk of microalbuminuria and risk of macroalbuminuria or proteinuria. Regarding all the other outcomes (vision loss, surgery of cataract, proliferative or non-proliferative retinopathy, death related to kidney disease, development of kidney disease, doubling of serum creatinine, neuropathy), no significant result was found., (Copyright © 2021 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
181. A randomized controlled phase III study comparing hadrontherapy with carbon ions versus conventional radiotherapy - including photon and proton therapy - for the treatment of radioresistant tumors: the ETOILE trial.
- Author
-
Balosso J, Febvey-Combes O, Iung A, Lozano H, Alloh AS, Cornu C, Hervé M, Akkal Z, Lièvre M, Plattner V, Valvo F, Bono C, Fiore MR, Vitolo V, Vischioni B, Patin S, Allemand H, Gueyffier F, Margier J, Guerre P, Chabaud S, Orecchia R, and Pommier P
- Subjects
- Carbon adverse effects, Humans, Ions therapeutic use, Photons adverse effects, Prospective Studies, Protons, Quality of Life, Carcinoma, Adenoid Cystic, Heavy Ion Radiotherapy adverse effects, Proton Therapy adverse effects, Sarcoma drug therapy, Soft Tissue Neoplasms drug therapy
- Abstract
Background: Some cancers such as sarcomas (bone and soft tissue sarcomas) and adenoid cystic carcinomas are considered as radioresistant to low linear energy transfer radiation (including photons and protons) and may therefore beneficiate from a carbon ion therapy. Despite encouraging results obtained in phase I/II trials compared to historical data with photons, the spread of carbon ions has been limited mainly because of the absence of randomized medical data. The French health authorities stressed the importance of having randomized data for carbon ion therapy., Methods: The ETOILE study is a multicenter prospective randomized phase III trial comparing carbon ion therapy to either advanced photon or proton radiotherapy for inoperable or macroscopically incompletely resected (R2) radioresistant cancers including sarcomas and adenoid cystic carcinomas. In the experimental arm, carbon ion therapy will be performed at the National Center for Oncological Hadrontherapy (CNAO) in Pavia, Italy. In the control arm, photon or proton radiotherapy will be carried out in referent centers in France. The primary endpoint is progression-free survival (PFS). Secondary endpoints are overall survival and local control, toxicity profile, and quality of life. In addition, a prospective health-economic study and a radiobiological analysis will be conducted. To demonstrate an absolute improvement in the 5-year PFS rate of 20% in favor of carbon ion therapy, 250 patients have to be included in the study., Discussion: So far, no clinical study of phase III has demonstrated the superiority of carbon ion therapy compared to conventional radiotherapy, including proton therapy, for the treatment of radioresistant tumors., Trial Registration: ClinicalTrials.gov identifier: NCT02838602 . Date of registration: July 20, 2016. The posted information will be updated as needed to reflect protocol amendments and study progress., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
182. Place of a new radiological index in predicting pulp exposure before intervention for deep carious lesions.
- Author
-
Gasqui MA, Pérard M, Decup F, Monsarrat P, Turpin YL, Villat C, Gueyffier F, Maucort-Boulch D, Roche L, and Grosgogeat B
- Subjects
- Humans, Radiography, Reproducibility of Results, Retrospective Studies, Dental Caries diagnostic imaging, Dental Caries therapy, Dentin
- Abstract
Background: During interventions for deep caries lesions without severe symptoms, preserving pulpal vitality is important to ensure treatment success, improve organ prognosis, and decrease cost-effectiveness. Current pre-operative radiographs allow visual estimation but not accurate measurement of lesion depth., Purpose: Investigate the ability of ratio 'remaining/total dentin thickness' (RDT/TDT, as determined on pre-operative radiographs) to predict pulp exposure during excavation., Methods: This retrospective study (January 2018-June 2020) analyzed data on 360 patients. Four independent raters examined standard pre-operative radiographs and their contrasted versions. Lines put at the dentino-enamel junction, the floor of the carious lesion, and the pulp chamber wall allowed deriving RDT/TDT. Inter-rater agreements and concordance were assessed. A logistic regression accounting for measurement errors provided odds ratios that estimated the ability of the RDT/TDT to predict pulp exposure., Results: The median RDT/TDT ratio ranges were 16.8-26.5% on standard and 16.2-24.6% on contrasted radiographs. Inter-rater agreements on RDT/TDT were rather poor and inter-rater reliability was low and similar in standard and contrasted radiographs: the concordance correlation coefficients (95% CIs) were estimated at 0.46 (0.40; 0.51) and 0.46 (0.40; 0.52), respectively. The risk of pulp exposure increased by 2.5 times [odds ratio (95% CI) 2.57 (2.06; 3.20)] per 10-point decrease of the ratio on standard radiographs vs. 4.15 (3.15; 5.46) on contrasted radiographs., Conclusion: RDT/TDT ratio is potentially helpful in predicting pulp exposure. However, the measurement errors on RDT and TDT being non-negligible and the interrater agreements poor, there is still place for advances through development of an automated process that will improve reliability and reproducibility of pulp exposure risk assessment., Clinical Trial: Trial registration number. ClinicalTrials.gov NCT04607395, October 29, 2020., (© 2021. The Author(s), under exclusive licence to Japanese Society for Oral and Maxillofacial Radiology and Springer Nature Singapore Pte Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
183. Needs for re-intervention on restored teeth in adults: a practice-based study.
- Author
-
Decup F, Dantony E, Chevalier C, David A, Garyga V, Tohmé M, Gueyffier F, Nony P, Maucort-Boulch D, and Grosgogeat B
- Subjects
- Adult, Cross-Sectional Studies, Crowns, Dental Restoration Failure, Dental Restoration, Permanent, Humans, Professional Role, Artificial Intelligence, Dentists
- Abstract
Objectives: Evaluate the need for re-intervention on dental coronal restorations in adults seen in a network of general dental practitioners (ReCOL). MATERIALS AND METHODS: This observational, cross-sectional, multicenter study involved 40 practitioners and 400 patients. Coronal restoration failures (needing re-intervention for unsatisfactory outcomes) were assessed with a simplified rating scale of seven criteria from the FDI World Dental Federation. The oral health status, the risk factors, and Oral Health Impact Profile-14 were also examined. Previous restoration characteristics (extent, technique, material) were analyzed according to the need for re-intervention (yes/no), the age group, and the risk profile. Qualitative variables were compared between "re-intervention" and "no re-intervention" group using Fisher exact test., Results: The need for re-intervention was estimated at 74% (95% CI: 70; 79); it increased with age (49 to 90%), unfavorable risk profile (82 vs. 62%), and extent of the filling (32, 39, 44, and 44% on 1, 2, 3 surfaces, and crowns, respectively). More posterior than anterior teeth were restored (median per patient: 6 vs. 1) or needed re-intervention (median per patient: 1 vs. 0)., Conclusions: The needs for re-intervention in adults are still high within a context of ever-changing materials and techniques, simplified and rationalized decision-makings, and demands for patient involvement., Clinical Relevance: Meeting these needs requires the following: (i) consensus definitions and assessment methods for "failure" and (ii) reliable feedbacks on materials, procedures, and satisfaction. Building large and detailed databases fed by networks of motivated practitioners will help analyzing complex success/failure data by artificial intelligence and guiding treatment and research., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
184. Expected Evolution of COVID-19 Epidemic in France for Several Combinations of Vaccination Strategies and Barrier Measures.
- Author
-
Pageaud S, Pothier C, Rigotti C, Eyraud-Loisel A, Bertoglio JP, Bienvenüe A, Leboisne N, Ponthus N, Gauchon R, Gueyffier F, Vanhems P, Iwaz J, Loisel S, Roy P, and On Behalf Of The Group CovDyn Covid Dynamics
- Abstract
The outbreak of the SARS-CoV-2 virus, enhanced by rapid spreads of variants, has caused a major international health crisis, with serious public health and economic consequences. An agent-based model was designed to simulate the evolution of the epidemic in France over 2021 and the first six months of 2022. The study compares the efficiencies of four theoretical vaccination campaigns (over 6, 9, 12, and 18 months), combined with various non-pharmaceutical interventions. In France, with the emergence of the Alpha variant, without vaccination and despite strict barrier measures, more than 600,000 deaths would be observed. An efficient vaccination campaign (i.e., total coverage of the French population) over six months would divide the death toll by 10. A vaccination campaign of 12, instead of 6, months would slightly increase the disease-related mortality (+6%) but require a 77% increase in ICU bed-days. A campaign over 18 months would increase the disease-related mortality by 17% and require a 244% increase in ICU bed-days. Thus, it seems mandatory to vaccinate the highest possible percentage of the population within 12, or better yet, 9 months. The race against the epidemic and virus variants is really a matter of vaccination strategy.
- Published
- 2021
- Full Text
- View/download PDF
185. Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment.
- Author
-
Lengliné E, Peron J, Vanier A, Gueyffier F, Kouzan S, Dufour P, Guillot B, Blondon H, Clanet M, Cochat P, Degos F, Chevret S, Grande M, and Putzolu J
- Subjects
- Antineoplastic Agents adverse effects, France, Government Agencies, Humans, Molecular Targeted Therapy, Neoplasms genetics, Neoplasms pathology, Treatment Outcome, Antineoplastic Agents therapeutic use, Clinical Trials as Topic, Neoplasms drug therapy, Research Design, Technology Assessment, Biomedical
- Abstract
During the past decade, health technology assessment bodies have faced new challenges in establishing the benefits of new drugs for individuals and health-care systems. A topic of increasing importance to the field of oncology is the so-called agnostic regulatory approval of targeted therapies for cancer (independent of tumour location and histology) granted on the basis of basket trials. Basket trials in oncology offer the advantage of simultaneously evaluating treatments for multiple tumours, even rare cancers, in a single clinical trial. To address the novel challenges introduced by these trials, an interdisciplinary panel was convened on behalf of the Transparency Committee of the French National Authority for Health to clarify an approach designed to guarantee a transparent, reproducible, and fair assessment of histology-agnostic treatments for reimbursement by the French National Health Insurance Fund. The requirements of this approach include the need for randomisation, clinically relevant endpoints, appropriate correction for multiple significance testing, characterisation of subgroup heterogeneity, and validation of underlying biomarker assays. A prospectively designated external control is encouraged when the implementation of a direct comparison is deemed infeasible. We also underline the importance of recording outcomes from basket trials in a registry for use as future external controls., Competing Interests: Declaration of interests We declare no competing interests., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
186. Evaluation of High-Throughput SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical Sensitivity, Specificity, and Association with Virus Neutralization Test.
- Author
-
Bal A, Pozzetto B, Trabaud MA, Escuret V, Rabilloud M, Langlois-Jacques C, Paul A, Guibert N, D'Aubarède-Frieh C, Massardier-Pilonchery A, Fabien N, Goncalves D, Boibieux A, Morfin-Sherpa F, Pitiot V, Gueyffier F, Lina B, Fassier JB, and Trouillet-Assant S
- Subjects
- Adult, Aged, COVID-19 blood, COVID-19 Serological Testing methods, Cohort Studies, Female, Humans, Longitudinal Studies, Male, Neutralization Tests, Prospective Studies, SARS-CoV-2, Sensitivity and Specificity, Antibodies, Neutralizing blood, Antibodies, Viral blood, COVID-19 diagnosis
- Abstract
Background: The association between SARS-CoV-2 commercial serological assays and virus neutralization test (VNT) has been poorly explored in mild patients with COVID-19., Methods: 439 serum specimens were longitudinally collected from 76 healthcare workers with RT-PCR-confirmed COVID-19. The clinical sensitivity (determined weekly) of 9 commercial serological assays were evaluated. Clinical specificity was assessed using 69 pre-pandemic sera. Correlation, agreement, and concordance with the VNT were also assessed on a subset of 170 samples. Area under the ROC curve (AUC) was estimated at 2 neutralizing antibody titers., Results: The Wantai Total Ab assay targeting the receptor binding domain (RBD) within the S protein presented the best sensitivity at different times during the course of disease. The clinical specificity was greater than 95% for all tests except for the Euroimmun IgA assay. The overall agreement with the presence of neutralizing antibodies ranged from 62.2% (95%CI; 56.0-68.1) for bioMérieux IgM to 91.2% (87.0-94.2) for Siemens. The lowest negative percent agreement (NPA) was found with the Wantai Total Ab assay (NPA 33% (21.1-48.3)). The NPA for other total Ab or IgG assays targeting the S or the RBD was 80.7% (66.7-89.7), 90.3% (78.1-96.1), and 96.8% (86.8-99.3) for Siemens, bioMérieux IgG, and DiaSorin, respectively. None of the commercial assays have sufficient performance to detect a neutralizing titer of 80 (AUC < 0.76)., Conclusions: Although some assays show a better agreement with VNT than others, the present findings emphasize that commercialized serological tests, including those targeting the RBD, cannot substitute a VNT for the assessment of functional antibody response., (© American Association for Clinical Chemistry 2021. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
187. DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials.
- Author
-
Grenet G, Mekhaldi S, Mainbourg S, Auffret M, Cornu C, Cracowski JL, Gueyffier F, Lega JC, and Cucherat M
- Subjects
- Humans, Hypoglycemic Agents adverse effects, Incretins, Diabetes Mellitus, Type 2 drug therapy, Dipeptidyl-Peptidase IV Inhibitors adverse effects
- Published
- 2021
- Full Text
- View/download PDF
188. Effect of periodontal treatment on the glomerular filtration rate, reduction of inflammatory markers and mortality in patients with chronic kidney disease: A systematic review.
- Author
-
Delbove T, Gueyffier F, Juillard L, Kalbacher E, Maucort-Boulch D, Nony P, Grosgogeat B, and Gritsch K
- Subjects
- Humans, Glomerular Filtration Rate, Periodontitis complications, Periodontitis physiopathology, Periodontitis therapy, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic therapy
- Abstract
Aim: To assess the effect of periodontal treatment (PT) on glomerular filtration rate (GFR), systemic inflammation, or mortality in patients with chronic kidney disease (CKD)., Methods: A literature search was performed on PubMed and Web of Science databases on articles published until December 2019. The PRISMA guidelines were used throughout the manuscript., Results: Of the total studies found, only 18 met the inclusion criteria; four retrospective and 14 prospective studies (including 3 randomized controlled trials-RCT). After PT, 3 studies investigated GFR, 2 found significant improvement; 11 (including 2 RCTs) investigated C-reactive protein levels, 9 found a significant improvement (including the 2 RCTs); 5 (including 3 RCTs) investigated Interleukine-6 level, 4 found a significant improvement (including 2 RCTs) and 2 studies evaluated mortality, one (retrospective study) found a significant difference., Conclusions: Within the limitations of the present study, PT seems to improve CKD status, especially by reducing the systemic inflammation. Further RCTs are needed to confirm the results and specifically assess the influence of different types of PT in CKD patients. Taking into consideration the ability of PT to prevent further tooth loss and denutrition, early management of periodontitis is extremely important in patients with impaired renal function., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
189. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis.
- Author
-
Mainbourg S, Cucherat M, Provencher S, Bertoletti L, Nony P, Gueyffier F, Mismetti P, Grange C, Durieu I, Kilo R, Laporte S, Grenet G, and Lega JC
- Subjects
- Administration, Oral, Anticoagulants adverse effects, Dabigatran therapeutic use, Hemorrhage chemically induced, Hemorrhage drug therapy, Humans, Pyridones therapeutic use, Rivaroxaban adverse effects, Treatment Outcome, Atrial Fibrillation drug therapy, Stroke drug therapy
- Abstract
Aim: The direct oral anticoagulants (DOAC) have similar half-lives, but the dosing regimen varies between once daily (QD) or twice daily (BID). For some prescribers, the QD regimen improves compliance. Others prefer BID regimens to promote better stability of plasma concentrations, particularly in the event of missed doses. Limited level of evidence provides guidance about the best treatment strategy. The purpose of this study was to compare the treatment effect of QD vs. BID administration of DOACs in major orthopedic surgery (MOS), non-valvular atrial fibrillation (NVAF), venous thromboembolism (VTE), and acute coronary syndrome (ACS)., Methods: We conducted a systematic review up to April 2020. We included phase II clinical trials comparing DOAC QD vs BID with same daily dose. We extracted data for the occurrence of major thrombosis (proximal deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke) and major hemorrhage (ISTH criteria and recommendations of the European Medicines Agency for surgical patients). Relative risks (RR) were combined using a fixed and random effects weighted meta-analysis., Results: Twelve randomized, controlled, phase II trials were included (10,716 patients), representing 24 dosing regimen comparisons of apixaban, darexaban, edoxaban, rivaroxaban, letaxaban, and dabigatran. There was no difference for major thrombotic event (RR
BID/QD = 1.06, 95%IC 0.86-1.30) nor for major bleeding (RRBID/QD = 1.02, 95%IC 0.84-1.23) between the BID vs QD regimens, without heterogeneity (I2 = 0%)., Conclusion: Our study does not support a global difference in term of efficacy and safety of the BID and QD regimens of DOAC in MOS, NVAF, VTE and ACS., (Copyright © 2020 Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
190. Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France on volume and cost of drug deliveries, assessed with administrative databases.
- Author
-
Mari K, Rannou F, Guillemin F, Elegbede M, Gueyffier F, Badot G, and Mistretta F
- Subjects
- Adult, Analgesics therapeutic use, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Female, France, Humans, Osteoarthritis drug therapy, Pharmaceutical Preparations
- Abstract
With Osteoarthritis (oa): As one of the leading causes of disability in adults worldwide, its toll on patients and its economic burden for payers are substantial. The issue of change in OA management with the evolution of reimbursement schemes needs to be addressed., Objective: To assess the impact of terminating the reimbursement of symptomatic slow-acting drugs in OA (SYSADOAs) in France in terms of volume and cost, from a healthcare payer perspective., Principal Results: We obtained costs and volumes from French public national databases. We considered three exposure periods around cutoff dates according to decisions of decreased then terminated SYSADOA reimbursement. The periods included 19 345 (control), 20 066 (secondary), and 16 200 (primary) patients, respectively. Mean ages were 66.2 (±11.8), 65.3 (±11.6) and 64.6 (±11.5) years and about 70% were women. The volume of nonsteroidal anti-inflammatory drug (NSAID) deliveries estimated by defined daily doses (DDDs) decreased during the periods from 40.5 (±76.3) DDDs per patient in 2008 to 29.6 (±66.4) in 2015. The volume of analgesic deliveries increased slowly over the three periods, from 70.2 (±108.9) DDDs in 2008 to 76.9 (±123.1) in 2015 for all patients., Major Conclusions: Our results did not show a measurable impact of terminating SYSADOA reimbursement on the delivery of NSAIDs and analgesics or on hospitalizations. However, neither do they allow for concluding that terminating SYSADOA reimbursement did not generate an increase in deliveries of non-reimbursed drugs, with their associated potential risks for public health., Competing Interests: Declaration of Competing Interest G Badot was in the staff of Genevrier laboratory involved in the study. F Mistretta's institution received fees from Genevrier laboratory. F Rannou received fees for relevant activities outside of the submitted work from Pierre Fabre, Sanofi Aventis, Pfizer, Bayer, and Expansciences. No conflict of interest was reported by other authors., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
191. Assessment of serological techniques for screening patients for COVID-19 (COVID-SER): a prospective, multicentric study.
- Author
-
Trouillet-Assant S, Albert Vega C, Bal A, Nazare JA, Fascia P, Paul A, Massardier-Pilonchery A, D Aubarede C, Guibert N, Pitiot V, Lahousse M, Boibieux A, Makhloufi D, Simon C, Rabilloud M, Trabaud MA, Gueyffier F, and Fassier JB
- Subjects
- COVID-19 epidemiology, Female, Humans, Male, Prospective Studies, Serologic Tests, Antibodies, Viral analysis, COVID-19 diagnosis, Mass Screening methods, Pandemics, SARS-CoV-2 immunology
- Abstract
Introduction: The COVID-19 pandemic caused by SARS-CoV-2 threatens global public health, and there is an urgent public health need to assess acquired immunity to SARS-CoV-2. Serological tests might provide results that can be complementary to or confirm suspected COVID-19 cases and reveal previous infection. The performance of serological assays (sensitivity and specificity) has to be evaluated before their use in the general population. The neutralisation capacity of the produced antibodies also has to be evaluated., Methods and Analysis: We set up a prospective, multicentric clinical study to evaluate the performance of serological kits among a population of healthcare workers presenting mild symptoms suggestive of SARS-CoV-2 infection. Four hundred symptomatic healthcare workers will be included in the COVID-SER study. The values obtained from a control cohort included during the prepandemic time will be used as reference. A workflow was set up to study serological response to SARS-CoV-2 infection and to evaluate antibody neutralisation capacity in patients with a confirmed SARS-CoV-2 infection. The sensitivity and specificity of the tests will be assessed using molecular detection of the virus as a reference. The measurement of IgM and IgG antibodies will be performed once per week for 6 consecutive weeks and then at 6, 12, 18, 24 and 36 months after the diagnosis. The kinetics of IgM and IgG will determine the optimal period to perform serological testing. The proportion of false negative PCR tests in symptomatic subjects will be determined on the basis of subsequent seroconversions., Ethics and Dissemination: Ethical approval has been obtained from the national review board for biomedical research in April 2020 (Comité de Protection des Personnes Sud Méditerranée I, Marseille, France) (ID RCB 2020-A00932-37). Results will be disseminated through presentations at scientific meetings and publications in peer-reviewed journals., Trial Registration Number: NCT04341142., Competing Interests: Competing interests: AB has received grant from bioMérieux and has served as consultant for bioMérieux for work and research not related to this manuscript., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
192. Individual participant data meta-analysis to examine interactions between treatment effect and participant-level covariates: Statistical recommendations for conduct and planning.
- Author
-
Riley RD, Debray TPA, Fisher D, Hattle M, Marlin N, Hoogland J, Gueyffier F, Staessen JA, Wang J, Moons KGM, Reitsma JB, and Ensor J
- Subjects
- Humans, Meta-Analysis as Topic, Proportional Hazards Models, Data Analysis, Models, Statistical
- Abstract
Precision medicine research often searches for treatment-covariate interactions, which refers to when a treatment effect (eg, measured as a mean difference, odds ratio, hazard ratio) changes across values of a participant-level covariate (eg, age, gender, biomarker). Single trials do not usually have sufficient power to detect genuine treatment-covariate interactions, which motivate the sharing of individual participant data (IPD) from multiple trials for meta-analysis. Here, we provide statistical recommendations for conducting and planning an IPD meta-analysis of randomized trials to examine treatment-covariate interactions. For conduct, two-stage and one-stage statistical models are described, and we recommend: (i) interactions should be estimated directly, and not by calculating differences in meta-analysis results for subgroups; (ii) interaction estimates should be based solely on within-study information; (iii) continuous covariates and outcomes should be analyzed on their continuous scale; (iv) nonlinear relationships should be examined for continuous covariates, using a multivariate meta-analysis of the trend (eg, using restricted cubic spline functions); and (v) translation of interactions into clinical practice is nontrivial, requiring individualized treatment effect prediction. For planning, we describe first why the decision to initiate an IPD meta-analysis project should not be based on between-study heterogeneity in the overall treatment effect; and second, how to calculate the power of a potential IPD meta-analysis project in advance of IPD collection, conditional on characteristics (eg, number of participants, standard deviation of covariates) of the trials (potentially) promising their IPD. Real IPD meta-analysis projects are used for illustration throughout., (© 2020 The Authors. Statistics in Medicine published by John Wiley & Sons, Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
193. Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis.
- Author
-
Mainbourg S, Addario A, Samson M, Puéchal X, François M, Durupt S, Gueyffier F, Cucherat M, Durieu I, Reynaud Q, and Lega JC
- Subjects
- Humans, Recurrence, Giant Cell Arteritis drug therapy, Glucocorticoids therapeutic use
- Abstract
Objective: The relapse rate of patients with giant cell arteritis (GCA) treated with glucocorticoids (GCs) alone varied widely in observational series and randomized controlled trials (RCTs). The purpose of this systematic review was to evaluate the prevalence of relapse and predisposing factors in patients receiving GCs alone., Methods: We searched Medline up to December 2017. The prevalence of relapse was pooled using a random-effects model., Results: A total of 34 studies (2,505 patients), comprising 8 RCTs, were included. The overall prevalence of relapse was 47.2% (95% confidence interval 40.0, 54.3) with a high heterogeneity (I
2 = 93%). Prevalence of relapse was significantly higher for patients included in an RCT compared to those included in an observational study (P < 0.0001), but was not significantly different according to design (P = 0.06). The relapse rate was associated with year of publication (34 studies, rate increase of 8.3% for 1 decade; P < 0.0001) and with shorter GC regimens (17 studies, rate decrease of 1.7% for 1 additional month; P < 0.001), the duration of scheduled GC therapy being shorter in RCTs (12.8 months) compared to observational studies (28.8 months). The effective duration of GC therapy (P = 0.23), initial GC dose (P = 0.49), duration of follow-up (P = 0.14), sex (P = 0.29), and age (P = 0.43) were not associated with the prevalence of relapse., Conclusion: GCA relapses occur in half of patients and without improvement across decades in patients receiving GC alone, and the relapse rate is more related to short duration of GC administration than to the initial dose at induction. These results advocate for trial design with at least 12 months of GC therapy., (© 2019, American College of Rheumatology.)- Published
- 2020
- Full Text
- View/download PDF
194. Inconclusive efficacy of intervention on upper-limb function after tetraplegia: A systematic review and meta-analysis.
- Author
-
Mateo S, Di Marco J, Cucherat M, Gueyffier F, and Rode G
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Quadriplegia physiopathology, Randomized Controlled Trials as Topic, Treatment Outcome, Upper Extremity physiopathology, Young Adult, Electric Stimulation Therapy methods, Exercise Therapy methods, Neurological Rehabilitation methods, Quadriplegia rehabilitation
- Abstract
Background: Rehabilitation aims to improve hand-arm function, upper-limb strength, and functional independence that has been impaired by tetraplegia. On the basis of evidence derived from stroke rehabilitation, interventions aiming to increase intensity (i.e., duration and/or number of movements practiced) or alter brain plasticity (including motor imagery, virtual reality, transcranial direct-current or magnetic stimulations; i.e., neuromodulation) are now used during tetraplegic rehabilitation. However, no meta-analysis has investigated the efficacy of these interventions., Objective: This systematic review and meta-analysis investigated, separately, the efficacy of these interventions to alter hand-arm function, upper-limb strength, and functional independence of individuals with tetraplegia., Methods: Two independent reviewers followed the PROSPERO protocol (CRD42018098506) for this systematic review. MEDLINE, PEDro CENTRAL, and SCOPUS databases were searched for reports of randomized controlled trials of individuals with tetraplegia that were published in English. We performed a meta-analysis of intensive versus less intensive interventions and neuromodulation versus sham interventions considering hand-arm function, strength, and functional independence., Results: From 168 records identified, we included 29 studies (all but 1 were single-centre) in the systematic review (647 participants with C2 to T1 tetraplegia [American Spinal Injury Association impairment scale A to D]). Interventions lasted from 66 to 40,320min. Five studies were retained in the intensity meta-analyses and 5 in the neuromodulation meta-analyses. Overall, 3/5 and 1/5 studies had adequate methodology (Cochrane Risk of Bias score ≥6/10). For each outcome, the p-values for the overall effect were>0.05. Heterogeneity was low, but when analyzing intensity, it was moderate for functional independence and high for hand-arm function. Quality of evidence was very low to low., Conclusions: We can provide no recommendations for using intensive versus less intensive interventions or neuromodulation versus sham during tetraplegia rehabilitation. Further multicentre studies of high methodological quality are required to reduce uncertainty about the efficacy of these interventions., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
195. Publication language and the estimate of treatment effects of physical therapy on balance and postural control after stroke in meta-analyses of randomised controlled trials.
- Author
-
Hugues A, Di Marco J, Bonan I, Rode G, Cucherat M, and Gueyffier F
- Subjects
- Humans, Language, Publication Bias, Publications, Randomized Controlled Trials as Topic, Treatment Outcome, Physical Therapy Modalities, Postural Balance, Stroke Rehabilitation methods
- Abstract
Background: Findings regarding the impact of language bias on treatment effect estimates (TEE) are conflicting, and very few studies have assessed these impacts in rehabilitation. The purpose was to compare TEE between studies published in non-English language (SPNEL) and those published in English language (SPEL) included in a previously published meta-analysis assessing the effects of physical therapy on balance and postural control after stroke., Methods: Six databases were searched until January 2019. Two independent reviewers selected randomised trials, extracted data, and assessed risk of bias. We conducted subgroup meta-analyses according to the language of study publication, then compared TEE between SPEL and SPNEL subgroups by using a random-effects meta-regression model., Results: From 13,123 records, 132 SPEL (n = 5219) and 13 SPNEL (n = 693) were included. SPNEL had a weight in the pooled estimate (8.2%) significantly lower than SPEL (91.8%; p<0.001). Compared to SPEL, SPNEL had both significantly worse methodological quality (p = 0.002) and quality of reporting for blinding of outcome assessment (p<0.001); and a significantly worse quality of reporting for incomplete outcome data (p<0.001). SPNEL had a significantly worse precision (i.e. inverse of variance) of TEE than SPEL (p = 0.005). Overall, the TEE was not significantly different between SPNEL and SPEL (standardised mean difference -0.16, 95% confidence interval [-0.53; 0.22], heterogeneity I2 = 78%). However, when PT was compared to sham treatment or usual care, SPNEL significantly over-estimated treatment effects (SMD -0.68, 95%CI [-1.03; -0.33], I2 = 39%) compared to SPEL. Restriction of the search to SPEL only did not change the direction of TEE for 8 out of 9 comparisons., Conclusions: SPNEL had a worse methodological quality than SPEL and were likely to over-estimate treatment effect. If inclusion of SPNEL in a systematic review is considered to be relevant, the impact of such studies on TEE should be explored by sensitivity analyses to ensure the findings validity., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2020
- Full Text
- View/download PDF
196. Drug prescription goals in primary care: a cross-sectional study.
- Author
-
Bernard L, Ecochard R, Gueyffier F, and Letrilliart L
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Female, France, General Practice, General Practitioners statistics & numerical data, Goals, Humans, Male, Middle Aged, Physician-Patient Relations, Young Adult, Drug Prescriptions, General Practitioners psychology, Practice Patterns, Physicians', Primary Health Care
- Abstract
Background: Care goals are often implicit, although their identification is a key element of any prescription process. This study aimed to describe the clinical goals of drug prescriptions in general practice, their determinants and the agreement between physicians and patients., Methods: This was a cross-sectional study conducted by 11 resident trainees acting as observers in 23 general practices. The residents recorded the indication and main physician's goal for all drugs prescribed during five consultation days in each practice in December 2015, and the main patient's goal for a sub-sample of consultations. We used an eight-category generic classification of prescription goals, including three specific (mortality, morbidity and cure), three non-specific (symptoms, quality of life, functioning) and two non-specified (other goal, no goal) categories. Analyses were based on a multivariable, multilevel model and on the kappa statistic applied to the sub-sample of consultations., Results: The sample encompassed 2141 consultations and 5036 drugs. The main physicians' goal of drug prescriptions was to relieve symptoms (43.3%). The other goals were to decrease the risk of morbidity (22.4%), to cure disease (11.7%), to improve quality of life (10.6%), to decrease the risk of mortality (8.5%) and to improve functioning (1.8%). The choice of a specific goal was more frequent in patients with the following characteristics: over 50 (OR [1.09;1.15]), of male gender (OR [1.09;1.39]), with full financial coverage for a long-term condition (OR [1.47;1.97]), known by the physician (OR [1.19;2.23]), or with a somatic health problem (OR [2.56;4.17]). Cohen's kappa for drug prescription goals between the patients and the physicians was 0.26 (0.23-0.30)., Conclusions: Physicians' goals are poorly shared with patients. It remains to be assessed whether it is possible to collect and discuss information on prescription goals on a daily basis.
- Published
- 2020
- Full Text
- View/download PDF
197. Comparison of crossover and parallel-group designs for the identification of a binary predictive biomarker of the treatment effect.
- Author
-
Grenet G, Blanc C, Bardel C, Gueyffier F, and Roy P
- Abstract
Pros and cons of crossover design are well known for estimating the treatment effect compared to parallel-group design, but remain unclear for identifying and estimating an interaction between a potential biomarker and the treatment effect. Such 'predictive' biomarkers, or 'effect modifiers', help to predict the response to specific treatments. The purpose of this report was to better characterize the advantages and disadvantages of crossover versus parallel-group design to identify predictive biomarkers. The treatment effect, the effect of a binary biomarker and their interaction were modelled using a linear model. The intra-subject correlation in the crossover design was taken into account through an intra-class correlation coefficient. The variance-covariance matrix of the parameters was derived and compared. For both trial designs, the variance of the parameter estimating an interaction between the treatment effect and a potential predictive biomarker corresponds to the variance of the parameter estimating the treatment effect, multiplied by the inverse of the frequency of the candidate biomarker. The ratio of the variance of the interaction parameter in the crossover to the variance estimated in the parallel-group design depends on the complement of the intra-class correlation coefficient. When planning a clinical trial including a search for candidate biomarker, the frequency of the candidate biomarker helps design the sample size, and the intra-subject correlation of the outcome should be taken into account for choosing between parallel-group and crossover designs., (© 2019 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).)
- Published
- 2020
- Full Text
- View/download PDF
198. Dynamical modeling of pro- and anti-inflammatory cytokines in the early stage of septic shock.
- Author
-
Tallon J, Browning B, Couenne F, Bordes C, Venet F, Nony P, Gueyffier F, Moucadel V, Monneret G, and Tayakout-Fayolle M
- Subjects
- Adjuvants, Immunologic pharmacology, Anti-Inflammatory Agents therapeutic use, Cytokines metabolism, Cytokines therapeutic use, Female, Humans, Inflammation, Interleukin-10 metabolism, Interleukin-18 metabolism, Male, Models, Immunological, Sepsis immunology, Sepsis metabolism, Shock, Septic drug therapy, Shock, Septic immunology, Shock, Septic metabolism, Treatment Outcome, Adjuvants, Immunologic therapeutic use, Cytokines immunology, Sepsis drug therapy
- Abstract
A dynamical model of the pathophysiological behaviors of IL18 and IL10 cytokines with their receptors is tested against data for the case of early sepsis. The proposed approach considers the surroundings (organs and bone marrow) and the different subsystems (cells and cyctokines). The interactions between blood cells, cytokines and the surroundings are described via mass balances. Cytokines are adsorbed onto associated receptors at the cell surface. The adsorption is described by the Langmuir model and gives rise to the production of more cytokines and associated receptors inside the cell. The quantities of pro and anti-inflammatory cytokines present in the body are combined to give global information via an inflammation level function which describes the patient's state. Data for parameter estimation comes from the Sepsis 48 H database. Comparisons between patient data and simulations are presented and are in good agreement. For the IL18/IL10 cytokine pair, 5 key parameters have been found. They are linked to pro-inflammatory IL18 cytokine and show that the early sepsis is driven by components of inflammatory character.
- Published
- 2020
- Full Text
- View/download PDF
199. GoPerio - impact of a personalized video and an automated two-way text-messaging system in oral hygiene motivation: study protocol for a randomized controlled trial.
- Author
-
Garyga V, Pochelu F, Thivichon-Prince B, Aouini W, Santamaria J, Lambert F, Maucort-Boulch D, Gueyffier F, Gritsch K, and Grosgogeat B
- Subjects
- Belgium, France, Health Behavior, Health Knowledge, Attitudes, Practice, Humans, Motivational Interviewing, Multicenter Studies as Topic, Patient Compliance, Patient Satisfaction, Periodontal Diseases diagnosis, Periodontal Diseases etiology, Randomized Controlled Trials as Topic, Time Factors, Treatment Outcome, Health Education, Dental, Motivation, Oral Health, Oral Hygiene, Patient Education as Topic, Periodontal Diseases prevention & control, Telemedicine, Text Messaging, Video Recording
- Abstract
Background: Oral hygiene is of paramount importance for the preservation of oral health, and for patients affected by periodontal disease establishing an effective oral hygiene routine is the first step of therapy. Several clinical frameworks have been developed to foster behavior change, such as motivational interviewing. However, two obstacles can be identified. First, patients tend to forget the advice they were given during the consultation. Second, it is hard to maintain motivation in the long term, thus leading to relapse. An innovative eHealth solution was designed with the aim to tackle both obstacles and supplement the current clinical standard of care. The primary objective is to compare the full mouth plaque scores of study groups (eHealth plus standard of care versus standard of care only) at 8 weeks of follow up. The main secondary objective is to compare the full mouth bleeding score at 8 weeks of follow up., Methods/design: The "GoPerio" study is a multicenter, randomized, controlled trial assessing the impact of a novel eHealth concept for oral hygiene motivation (personalized video of oral hygiene routine available for the patient via a cloud server plus interactive text messages) in addition to the current standard of care (motivational interviewing plus tooth scaling and polishing). The minimum sample size required is 86 patients. Participants will be randomized (allocation ratio 1:1): test group (eHealth plus standard of care) versus control group (standard of care only). The primary outcome is oral hygiene as measured by the full mouth (six sites per tooth) plaque control record (PCR) index. The main secondary outcome is gingival inflammation as measured by the full mouth (six sites per tooth) bleeding on probing (BOP) index. Both the primary and the main secondary outcomes are evaluated by blinded and calibrated examiners at 8 weeks of follow up. The other secondary outcomes are patient satisfaction and patient behavior change and motivation., Discussion: The study will investigate the value of an innovative eHealth approach to strengthen patient motivation for oral hygiene. If proven effective, such an approach would supplement the current clinical standard of care, resulting in improved clinical outcomes with negligible impact on productivity in a dental practice., Trial Registration: ClinicalTrials.gov, NCT03109808. Registered on 12 April 2017., Sponsor: Hospices Civils de Lyon. BP 2251, 3 quai des Célestins, 69,229 Lyon cedex 02. Protocol version: 1.0 as of 21 September 2016.
- Published
- 2019
- Full Text
- View/download PDF
200. Association between difference in blood pressure reduction and risk of cardiovascular events in a type 2 diabetes population: A meta-regression analysis.
- Author
-
Grenet G, Le HH, Bejan-Angoulvant T, Erpeldinger S, Boussageon R, Kassaï B, Moulin P, Gueyffier F, and Cucherat M
- Subjects
- Cardiovascular Diseases mortality, Diabetes Mellitus, Type 2 complications, Diabetic Angiopathies epidemiology, Diabetic Angiopathies mortality, Diabetic Angiopathies prevention & control, Humans, Hypertension complications, Hypertension drug therapy, Myocardial Infarction etiology, Myocardial Infarction mortality, Randomized Controlled Trials as Topic statistics & numerical data, Regression Analysis, Risk Factors, Stroke etiology, Stroke mortality, Antihypertensive Agents therapeutic use, Blood Pressure drug effects, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 epidemiology
- Abstract
Aim: Recent US recommendations indicate a target blood pressure (BP) of 130/80mmHg for patients with type 2 diabetes (T2D). Our aim was to characterize the association between risk of cardiovascular events and differences in BP decreases in randomized trials of a T2D population., Methods: A systematic search was made for randomized clinical trials assessing the effects of antihypertensive treatments in T2D patients on mortality, and fatal and non-fatal cardiovascular events, using a meta-regression technique to explore the influence of BP decreases on treatment effects., Results: A total of 88,503 patients from 44 randomized trials were included. There was no significant association between BP decreases and risk of all-cause or cardiovascular mortality, cardiovascular events or myocardial infarction. However, stroke risk was influenced by BP decreases: compared with no reduction, a 10-mmHg reduction in systolic BP was associated with a relative odds ratio (OR) decrease of 33% (OR: 0.67, 95% CI: 0.54-0.82), and a 5-mmHg diastolic BP reduction was associated with a relative OR decrease of 38% (OR: 0.62, 95% CI: 0.50-0.76). Restricting the analysis to double-blind studies did not change the results for diastolic BP., Conclusion: A reduction in BP lowers the risk of stroke, but does not appear to affect the risk of other cardiovascular events in a T2D population., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.